Mitragyna-Cannabinoid Synergy for Low-Dose Topical Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical and cosmetic preparations containing Mitragyna speciosa and Cannabis sativa extracts often require high concentrations of active principles, leading to significant side effects such as addiction, liver damage, and cognitive impairments, while high cannabinoid doses also cause adverse effects.
Innovation Solution
A composition with low concentrations of Mitragyna speciosa alkaloids (0.00001 wt.-% to 5 wt.-%) and Cannabis sativa cannabinoids (0.00001 wt.-% to 5 wt.-%) in combination, preferably as extracts or isolated compounds, showing synergistic effects for treating skin and mucosal disorders with reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high concentrations of Mitragyna speciosa and Cannabis sativa extracts are used to achieve therapeutic effects, then treatment effectiveness is improved, but side effects such as addiction, liver damage, and cognitive impairments increase
Solution Approach 1:
The patent combines Cannabis extract with Mitragyna speciosa extract to create a synergistic formulation. This merging of two different plant extracts allows the formulation to achieve therapeutic effects at lower concentrations, thereby reducing side effects while maintaining treatment effectiveness.
Solution Approach 2:
The patent changes the concentration parameters of the active ingredients by using standardized extracts with defined alkaloid content (0.01-5% mitragynine and/or 7-hydroxymitragynine) and cannabinoid content. This parameter optimization allows achieving therapeutic effects at lower doses, reducing harmful effects while maintaining efficacy.
2Reliability
If high amounts of cannabinoids are used to treat skin disorders, then anti-inflammatory and anti-pruritic effects are improved, but cognitive impairments and other adverse effects increase
Solution Approach 1:
Mitragyna speciosa extract acts as an intermediary that enhances the therapeutic effects of cannabinoids while reducing their harmful effects. The combination allows for lower cannabinoid dosing, mediating between the desired anti-inflammatory effect and the avoidance of cognitive impairments.
Solution Approach 2:
The patent creates a composite formulation combining two plant extracts with complementary mechanisms of action. This composite material approach allows synergistic effects that achieve therapeutic outcomes at lower concentrations of individual active ingredients, reducing adverse effects.
3Reliability
If high concentrations of Mitragyna alkaloids are used to achieve analgesic effects, then pain relief is improved, but addiction and liver damage increase
Solution Approach 1:
The patent uses partial action by combining Mitragyna alkaloids with cannabinoids, where the combination produces analgesic effects at lower concentrations of Mitragyna alkaloids than would be required alone. This partial dosing approach reduces the risk of addiction and liver damage while maintaining pain relief efficacy.
Data Source
AI summary
A cosmetic and pharmaceutical preparation for topical use contains from about 0.00001 wt.-% to about 20 wt.-%, of one or more alkaloids of Mitragyna speciosa and from about 0.00001 wt.-% to about 20 wt.-% of one or more cannabinoids of Cannabis indica or Cannabis sativa. The preparation is intended for use in preventing and/or treating skin and mucosal disorders and conditions.